People with lung cancer who are treated with the drug Tarceva face a daunting uncertainty. The uncertainty dawns around the fact that their tumors may initially shrink, it's not a question of whether their cancer will return-it's a question of when. And for far too many, it happens far too soon.
Now, a team of researchers at the University of California, San Francisco's Helen Diller Family Comprehensive Cancer Center has discovered that a human protein called AXL drives resistance to Tarceva, ...
People with lung cancer who are treated with the drug Tarceva face a daunting uncertainty. The uncertainty dawns around the fact that their tumors may initially shrink, it's not a question of whether their cancer will return-it's a question of when. And for far too many, it happens far too soon.
Now, a team of researchers at the University of California, San Francisco's Helen Diller Family Comprehensive Cancer Center has discovered that a human protein called AXL drives resistance to Tarceva, ...